摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

伊加地平 | 119687-33-1

中文名称
伊加地平
中文别名
——
英文名称
Iganidipine
英文别名
5-O-[2,2-dimethyl-3-(4-prop-2-enylpiperazin-1-yl)propyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
伊加地平化学式
CAS
119687-33-1;788791-04-8;752171-43-0
化学式
C28H38N4O6
mdl
——
分子量
526.6
InChiKey
QBTSPDQKRVMTRU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    溶于二甲基亚砜

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    38
  • 可旋转键数:
    11
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    117
  • 氢给体数:
    1
  • 氢受体数:
    9

制备方法与用途

生物活性

Iganidipine 是一种钙离子通道拮抗剂。

靶点

Ca²⁺

体内研究

在兔子身上,单次给予0.03% Iganidipine 溶液后,视神经头(ONH)组织的血液流速(NBONH)显著增加了8-10%,且具有统计学意义(p < 0.05)。连续21天、每日两次给予Iganidipine 后,该数值增加至18-35%。在猴子身上,0.03% 和 0.1% 的 Iganidipine 在7天内每天两次给药后分别增加了20% 和41% 的血液流速(p < 0.05)。

文献信息

  • Nitrogen-containing tricyclic compounds
    申请人:Yamada Rintaro
    公开号:US20060247266A1
    公开(公告)日:2006-11-02
    A novel compound represented by the following formula (1) or a salt thereof [wherein R 1 , R 5 , R 6 , R 7 , and R 8 represent hydrogen atom, a halogen atom, hydroxyl group, an alkyl group, an alkenyl group and the like; X 1 . . . X 2 represents —CH(R 2 )—CH(R 3 )—, —CH(R 2 )—CH(R 3 )—CH(R 4 )—, —C(R 2 )═C(R 3 )—, or —C(R 2 )═C(R 3 )—CH(R 4 )—(R 2 , R 3 , and R 4 represent hydrogen atom, or an alkyl group); A 1 , A 11 , A 2 , and A 21 represent hydrogen atom, or an alkyl group; Y represents —CH(A 3 )-, —CH(A 3 )-C(A 4 )(A 41 )-, —CH(A 3 )-C(A 4 )(A 41 )-C(A 5 )(A 51 )-, or a single bond (A 3 , A 4 , A 41 , A 5 , and A 51 represent hydrogen atom, or an alkyl group), and Z represents hydroxyl group, or —N(A 6 )(A 61 )(A 6 represents hydrogen atom, or an alkyl group, and A 61 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like)], having an action of potently inhibiting phosphorylation of myosin regulatory light chain.
    以下式(1)表示的新化合物或其盐[其中R1、R5、R6、R7和R8代表氢原子、卤素原子、羟基、烷基、烯基等;X1...X2代表—CH(R2)—CH(R3)—、—CH(R2)—CH(R3)—CH(R4)—、—C(R2)=C(R3)—或—C(R2)=C(R3)—CH(R4)—(R2、R3和R4代表氢原子或烷基);A1、A11、A2和A21代表氢原子或烷基;Y代表—CH(A3)-、—CH(A3)-C(A4)(A41)-、—CH(A3)-C(A4)(A41)-C(A5)(A51)-或单一键(A3、A4、A41、A5和A51代表氢原子或烷基),Z代表羟基或—N(A6)(A61)(A6代表氢原子或烷基,A61代表氢原子、烷基、取代烷基等)]具有强烈抑制肌球蛋白调节轻链磷酸化的作用。
  • AROMATIC AMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICAL USES OF BOTH
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:EP1813603A1
    公开(公告)日:2007-08-01
    A present invention provides aromatic amide derivatives which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like, and are represented by the general formula (I): wherein R1 represents a hydrogen atom or a C1-6 alkyl group which may have a substituent, R2 is a hydrogen atom or a C1-6 alkyl group, R3 is a hydrogen atom, a C1-6 alkyl group or the like, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, R7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C3-8 cycloalkyl group', an amino group which may have a substituent or a C1-6 alkoxy group which may have a substituted group; M1 is a single bond, a C1-4 alkylene group or the like Y is N or CRF (in the formula, RF represents a hydrogen atom, a C1-6 alkyl group or the like or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.
    本发明提供了具有V2受体激动作用的芳香酰胺衍生物,可用作治疗或预防尿崩症、夜尿症、夜间遗尿、膀胱过度活跃或类似疾病的药物,并由通式(I)表示: 其中R1代表氢原子或可能具有取代基的C1-6烷基基团,R2是氢原子或C1-6烷基基团,R3是氢原子、C1-6烷基基团或类似物,R4、R5和R6独立地是氢原子、卤原子或类似物,R7是氢原子、可能具有取代基的杂环基团、C3-8环烷基团、可能具有取代基的基团或可能具有取代基的C1-6烷氧基团;M1是单键、C1-4烷基烃基团或类似物,Y是N或CRF(在该式中,RF代表氢原子、C1-6烷基基团或类似物),或其药学上可接受的盐,或其前药,或包含其的药物组合物和药物用途。
  • UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:EP1867639A1
    公开(公告)日:2007-12-19
    Urea derivatives represented by the following general formula (I) : which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the formula, R1 represents a hydrogen atom or a C1-6 alkyl group which may have a substituent, R2 is a hydrogen atom or a C1-6 alkyl group, R3 is a hydrogen atom, a C1-6 alkyl group or the like, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, R7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C3-8 cycloalkyl group, an amino group which may have a substituent or a C1-6 alkoxy group which may have a substituted group, M1 is a single bond, a C1-4 alkylene group or the like, Y is N or CRF (in the formula, and RF represents a hydrogen atom, a C1-6 alkyl group or the like, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.
    以下一般公式(I)所代表的尿素生物,具有V2受体的激动作用,可用作治疗或预防尿崩症、夜尿、夜间遗尿、膀胱过度活动等药物。在公式中,R1代表氢原子或可能具有取代基团的C1-6烷基;R2是氢原子或C1-6烷基;R3是氢原子、C1-6烷基或其他基团;R4、R5和R6独立地是氢原子、卤素原子或其他基团;R7是氢原子、可能具有取代基团的杂环烷基、C3-8环烷基、可能具有取代基团的基或可能具有取代基团的C1-6烷氧基;M1是单键、C1-4烷基或其他基团;Y是N或CRF(在公式中,RF代表氢原子、C1-6烷基或其他基团),或其药学上可接受的盐、前药、包含相同成分的药物组合物及其药用。
  • Sulfonamide compound
    申请人:Matsubara Koki
    公开号:US20090048223A1
    公开(公告)日:2009-02-19
    A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G 1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G 2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; G 3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkoxycarbonyl group, an acyl group, an acyloxy group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; Y represents a single bond, or —C(R 3 )(R 4 )— (R 3 and R 4 represent hydrogen atom, or an alkyl group, or alkylene groups which combine together to form a saturated hydrocarbon ring group); G 4 represents hydroxyl group (Y is a single group), or —N(R 1 )(R 2 ) (R 1 and R 2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, a saturated heterocyclic group, an alkylsulfonyl group, an acyl group, or an amidino group); G 5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.
    由以下化学式表示的化合物:[A代表含氮饱和环;m表示0到2的整数;n表示1到4的整数;G1代表氢原子、原子、羟基、烷氧基或基;G2代表卤原子、羟基、基、羧基、烷基、烯基、炔基、烷氧基、烷基、基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基;G3代表氢原子、卤原子、羟基、基、羧基、烷基、烯基、炔基、烷氧基、烷基、基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基;Y代表单键,或-C(R3)(R4)-(R3和R4代表氢原子、烷基或烷烯基,它们结合在一起形成饱和碳氢环基);G4代表羟基(Y是单个基),或-N(R1)(R2)(R1和R2代表氢原子、烷基、芳基、烯基、炔基、饱和杂环基、烷基磺酰基、酰基或胺基);G5是A的环构成碳原子上的取代基,代表氢原子、原子或烷基]或其盐、或作为前药的衍生物,其强力抑制Rho激酶。
  • SULFONAMIDE COMPOUND
    申请人:Yamada Rintaro
    公开号:US20100093789A1
    公开(公告)日:2010-04-15
    A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G 1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G 2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, and the like; G 3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, and the like; G 4 represents hydroxyl group, or —N(R 1 )(R 2 ) (R 1 and R 2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, or a saturated heterocyclic group); G 5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.
    化合物由以下公式表示(1) [A代表含氮饱和环;m表示0到2的整数;n表示1到4的整数;G1代表氢原子、原子、羟基、烷氧基或基;G2代表卤原子、羟基、基、羧基、烷基、烯基等;G3代表氢原子、卤原子、羟基、基、羧基、烷基、烯基等;G4代表羟基,或-N(R1)(R2) (R1和R2代表氢原子、烷基、芳基烷基、烯基、炔基或饱和杂环基);G5是A的环构成碳原子上的取代基,代表氢原子、原子或烷基]或其盐,或其作为前药的衍生物,强力抑制Rho激酶。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-